Nasdaq rings in Jonathan Lim's next cancer play, Pfizer-backed startup and Harvard spinout with collective $534M raise under their belts
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
IPOs are booming in 2021, and companies are going public earlier than ever.
About 45% of IPOs offered in the first half of the year were for companies that were still in preclinical and discovery stages. That’s a big change for the 66 biopharma therapeutics and platform companies who completed their IPO in the first half of the year, raising $9.3 billion in total.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.